MediPearl follows current Good Clinical Practice (cGCP) and conducts our pivotal human trials of our plant-derived products in collaboration with local clinical trial centers. A phase I/II trial on Proveq MPCB was conducted at Department of Medical Oncology, Singapore General Hospital in advanced lung cancer patients who had failed all conventional chemotherapy. Patients were accrued and given MPCB, for three months, in escalated doses. Proveq MPCB is well tolerated even up to 7.2 g per day. Patient responded well and median survival time was extended from the expected 4.5 months to 9.5 months for the entire group.